Lessons From the ARCHER Trial - Takeaways - MDSpire

Lessons From the ARCHER Trial

Margaret A. Chang, MD, MS, discusses how findings from the phase 2 ARCHER trial informed the design of the ongoing phase 3 ARCHER II study of vonaprument, which is expected to read out later this year.

  • By

  • Margaret Chang, MD

  • July 15, 2026

  • 2 min

Share

  • 1

    The ARCHER trial focused on the effects of vonaprument on vision loss in patients with geographic atrophy.

  • 2

    Vonaprument targets C1q, a key trigger in the classical complement cascade associated with neurodegenerative diseases.

  • 3

    Patients with baseline vision between 20/40 and 20/100 were identified as having the highest risk for 15-letter vision loss.

  • 4

    Subfoveal lesions were found to increase the risk of 15-letter vision loss compared to nonsubfoveal lesions.

  • 5

    Findings from the ARCHER trial informed the design of the ongoing phase 3 ARCHER II study, expected to report results later this year.

Original Source(s)

Lessons From the ARCHER Trial

  • by Margaret Chang, MD

  • July 15, 2026

Related Content

The Promise of Gene Therapy

With phase 3 topline data for sura-vec expected later this year, Arshad M. Khanani, MD, FASRS, reflects on how gene therapy could transform long-term treatment for nAMD.

ASRS President Reflects on a Year of Change

As his term comes to a close, Geoffrey G. Emerson, MD, PhD, FASRS, discusses scientific advances, physician advocacy, and the collaborative leadership behind ASRS.

Merck Highlights Early Tiespectus Data

At the ASRS meeting in Montreal, Baruch D. Kuppermann, MD, PhD, presented BRVO findings from the phase 1/2a RIOJA program evaluating the investigational VEGF/Tie2 bispecific.